Survival continues to increase in chronic lymphocytic leukaemia: a population‐based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016

Lina van der Straten(Erasmus MC), Avinash G. Dinmohamed(Erasmus MC), Mark‐David Levin(Albert Schweitzer Ziekenhuis), Otto Visser(Netherlands Comprehensive Cancer Organisation), Arnon P. Kater(Sanford Burnham Prebys Medical Discovery Institute), Eduardus F. M. Posthuma(Leiden University Medical Center), Jeanette K. Doorduijn(Université Paris Cité)
British Journal of Haematology
January 20, 2020
10.1111/bjh.16397
Cited by 18

Related Papers

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis
|Journal of Clinical Oncology|2010|478
Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands
|Annals of Oncology|2012|173